tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
Ocugen Inc (OCGN)
NASDAQ:OCGN
US Market
OCGN
Ocugen
Overview
Analyst Forecasts
Financials
Dividends
Technical Analysis
Options
Chart
Earnings
Ownership
Stock Buybacks
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports

Ocugen (OCGN) Stock News & Sentiment

Compare
5,828 Followers
Buy Rating for Ocugen Based on Promising OCU410 Study Progress and Geographic Atrophy Treatment Potential
Premium
Ratings
Buy Rating for Ocugen Based on Promising OCU410 Study Progress and Geographic Atrophy Treatment Potential
6d ago
OCGN
OCGN Stock: Can New Leadership Save This Biotech Company?
Premium
Market News
OCGN Stock: Can New Leadership Save This Biotech Company?
3M ago
OCGN
Ocugen Appoints Ramesh Ramachandran as Financial Officer
Premium
Company Announcements
Ocugen Appoints Ramesh Ramachandran as Financial Officer
3M ago
8K
OCGN
Ocugen to Present Innovations at Nasdaq Clinical Showcase
Premium
Company Announcements
Ocugen to Present Innovations at Nasdaq Clinical Showcase
3M ago
8K
OCGN
Ocugen: Progress in Gene Therapy and Financial Outlook
Premium
Company Announcements
Ocugen: Progress in Gene Therapy and Financial Outlook
3M ago
OCGN
OCGN Earnings: Ocugen’s Q3 Results Disappoint
Premium
Market News
OCGN Earnings: Ocugen’s Q3 Results Disappoint
3M ago
OCGN
Options Volatility and Implied Earnings Moves Today, November 08, 2024
Premium
Market News
Options Volatility and Implied Earnings Moves Today, November 08, 2024
3M ago
TU
BAX
More OCGN News >

OCGN News on the Web

Why Ocugen Is Advancing Today
Yahoo Finance
Neutral
Analysts Offer Insights on Healthcare Companies: Ocugen (OCGN) and Xilio Therapeutics (XLO)
TipRanks News
Bullish
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Yahoo Finance
Neutral
Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa
Yahoo Finance
Neutral
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
Yahoo Finance
Neutral
Ocugen’s Promising Pipeline and Strategic Advancements Bolster Buy Rating
TipRanks News
Bullish
Ocugen doses first subject in Phase I trial of diabetic macular oedema treatment
Clinical Trials Arena
Neutral
Ocugen’s OCU400: Promising Clinical Efficacy and Strong Buy Rating Amidst Valuation and Safety Confidence
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
OCGN
Sector Average
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
This Week100%
Sector Average58%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is OCGN’s Media Buzz Sentiment?
Currently, no data Available
What is OCGN’s weekly average amount of articles?
Currently, no data Available
What is OCGN’s News Sentiment?
100% of articles about OCGN were positive this week, compared to its sector average of 58%.
    Healthcare Stocks that are Trending in the News
    BNTCBenitec Biopharma
    SHGSingular Health Group Ltd
    RCUSArcus Biosciences
    HCMHUTCHMED
    PENPenumbra
    Showing the stocks with the most bullish news sentiment over the past week

    Become an Expert with TipRanks Premium

    What am I Missing?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis
    Subscribe NowSee Plans & Pricing